X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-06 | EIKN | Eikon Therapeutics, Inc. | Column Group IV Gp, LP | 10% | P - Purchase | $18.00 | +2,117,760 | 5,780,143 | +58% | +$38,119,680 | |||||
2026-02-06 | TWST | Twist Bioscience Corp | Johannessen Jan | Dir | S - Sale | $47.91 | -2,200 | 17,754 | -11% | -$105,395 | ||||||
| D | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Foresite Capital Management Iv, LLC | 10% | P - Purchase | $18.00 | +55,555 | 1,318,983 | +4% | +$999,990 | |||||
| D | 2026-02-04 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale+OE | $18.46 | -2,145 | 216,637 | -1% | -$39,597 | |||||
2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Frazier Kenneth C | Dir | P - Purchase | $18.00 | +111,111 | 111,111 | New | +$1,999,998 | ||||||
| D | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Wolfe Josh | Dir, 10% | P - Purchase | $18.00 | +277,776 | 2,294,653 | +14% | +$4,999,968 | |||||
| D | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Lux Venture Partners V, LLC | 10% | P - Purchase | $18.00 | +277,776 | 2,294,653 | +14% | +$4,999,968 | |||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Howton David T | COO | S - Sale | $6.44 | -18,894 | 97,859 | -16% | -$121,713 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Pres, CEO | S - Sale | $6.44 | -48,913 | 222,018 | -18% | -$315,093 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale | $6.44 | -7,205 | 143,962 | -5% | -$46,414 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale | $6.44 | -14,783 | 94,201 | -14% | -$95,231 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale | $6.44 | -12,616 | 84,092 | -13% | -$81,271 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Chief Regulatory Officer | S - Sale | $6.44 | -12,348 | 70,327 | -15% | -$79,545 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Herzich Paul | CTO | S - Sale | $6.44 | -10,905 | 69,067 | -14% | -$70,249 | ||||||
| D | 2026-02-04 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $4.12 | -40,000 | 933,821 | -4% | -$164,800 | |||||
2026-02-03 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.20 | -220,000 | 6,429,863 | -3% | -$924,000 | ||||||
2026-02-04 | TSHA | Taysha Gene Therapies, Inc. | Alam Kamran | CFO | S - Sale | $4.52 | -1,655 | 1,442,131 | 0% | -$7,481 | ||||||
| D | 2026-02-05 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale+OE | $150.00 | -115,640 | 613,912 | -16% | -$17,346,000 | |||||
| DM | 2026-02-03 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $77.07 | -50,000 | 708,719 | -7% | -$3,853,503 | |||||
2026-02-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $1.82 | -323 | 514,551 | 0% | -$589 | ||||||
2026-02-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $46.58 | -2,705 | 307,788 | -1% | -$125,988 | ||||||
2026-02-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $46.58 | -1,099 | 143,581 | -1% | -$51,187 | ||||||
| D | 2026-02-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $46.58 | -5,001 | 869,312 | -1% | -$232,927 | |||||
| M | 2026-02-03 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $45.67 | -7,175 | 58,738 | -11% | -$327,687 | |||||
2026-02-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $46.58 | -1,194 | 165,445 | -1% | -$55,612 | ||||||
| D | 2026-02-04 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $65.79 | -5,500 | 211,148 | -3% | -$361,860 | |||||
2026-02-02 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $65.81 | -2,000 | 183,371 | -1% | -$131,630 | ||||||
| M | 2026-02-02 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $18.68 | -42,788 | 1,179,524 | -4% | -$799,105 | |||||
2026-02-02 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $18.44 | -124,998 | 2,459,245 | -5% | -$2,304,963 | ||||||
| D | 2026-02-04 | ATYR | Atyr Pharma Inc | Shukla Sanjay | Pres, CEO | S - Sale+OE | $0.98 | -3,745 | 153,553 | -2% | -$3,655 | |||||
| D | 2026-02-04 | ATYR | Atyr Pharma Inc | Broadfoot Jill Marie | CFO | S - Sale+OE | $0.98 | -1,558 | 37,296 | -4% | -$1,521 | |||||
| D | 2026-02-04 | ATYR | Atyr Pharma Inc | Denyes Nancy | GC | S - Sale+OE | $0.98 | -1,118 | 33,124 | -3% | -$1,091 | |||||
2026-02-04 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.13 | +5,000 | 273,866 | +2% | +$5,650 | ||||||
| D | 2026-02-02 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | S - Sale+OE | $1.73 | -7,549 | 210,172 | -3% | -$13,060 | |||||
| D | 2026-02-02 | ALLO | Allogene Therapeutics, Inc. | Chang David D | Pres, CEO | S - Sale+OE | $1.80 | -95,269 | 8,099,058 | -1% | -$171,484 | |||||
| D | 2026-02-02 | ALLO | Allogene Therapeutics, Inc. | Parker Geoffrey M. | CFO | S - Sale+OE | $1.76 | -24,001 | 1,252,795 | -2% | -$42,242 | |||||
| D | 2026-02-02 | ALLO | Allogene Therapeutics, Inc. | Douglas Earl Martin | SVP, GC | S - Sale+OE | $1.76 | -22,900 | 564,948 | -4% | -$40,304 | |||||
| D | 2026-02-02 | ALLO | Allogene Therapeutics, Inc. | Yoshiyama Annie | SVP, Finance | S - Sale+OE | $1.72 | -4,167 | 130,322 | -3% | -$7,167 | |||||
| D | 2026-02-02 | ALLO | Allogene Therapeutics, Inc. | Roberts Zachary | EVP of R, D | S - Sale+OE | $1.77 | -35,700 | 581,166 | -6% | -$63,189 | |||||
| D | 2026-02-02 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $46.02 | -15,000 | 0 | -100% | -$690,334 | |||||
| D | 2026-02-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $46.04 | -5,000 | 12,965 | -28% | -$230,219 | |||||
| M | 2026-01-30 | SRZN | Surrozen, Inc./De | Tcg Crossover Gp Ii, LLC | 10% | P - Purchase | $21.65 | +9,357 | 641,682 | +1% | +$202,534 | |||||
| D | 2026-02-02 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale+OE | $179.30 | -748 | 6,271 | -11% | -$134,116 | |||||
2026-02-02 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $7.71 | -22,000 | 1,144,391 | -2% | -$169,671 | ||||||
| D | 2026-02-02 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale+OE | $6.44 | -26,837 | 108,984 | -20% | -$172,747 | |||||
| D | 2026-02-02 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Pres, CEO | S - Sale+OE | $6.44 | -80,258 | 270,931 | -23% | -$516,613 | |||||
| D | 2026-02-02 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Chief Regulatory Officer | S - Sale+OE | $6.44 | -26,535 | 82,675 | -24% | -$170,803 | |||||
| D | 2026-02-02 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale+OE | $6.44 | -28,335 | 96,708 | -23% | -$182,390 | |||||
| D | 2026-02-02 | SLDB | Solid Biosciences Inc. | Howton David T | COO | S - Sale+OE | $6.44 | -37,771 | 116,753 | -24% | -$243,128 | |||||
| D | 2026-02-02 | SLDB | Solid Biosciences Inc. | Herzich Paul | CTO | S - Sale+OE | $6.44 | -26,250 | 79,972 | -25% | -$168,969 | |||||
2026-01-30 | ELUT | Elutia Inc. | Rakin Kevin | Dir, 10% | P - Purchase | $1.06 | +70,000 | 5,225,098 | +1% | +$74,200 | ||||||
| D | 2026-02-02 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale+OE | $7.76 | -10,349 | 98,477 | -10% | -$80,308 | |||||
2026-01-29 | DBVT | Dbv Technologies S.A. | Mohideen Pharis | Chief Medical Officer | S - Sale | $4.86 | -534 | 144,995 | 0% | -$2,595 | ||||||
| D | 2026-01-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $44.27 | -7,500 | 10,503 | -42% | -$331,990 | |||||
| DM | 2026-01-29 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale+OE | $28.87 | -50,000 | 1,089,667 | -4% | -$1,443,528 | |||||
2026-01-30 | ELUT | Elutia Inc. | Neels Guido J | Dir | P - Purchase | $1.04 | +20,000 | 118,750 | +20% | +$20,800 | ||||||
| D | 2026-01-28 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $6.59 | -191 | 136,167 | 0% | -$1,259 | |||||
| M | 2026-01-28 | ELUT | Elutia Inc. | Neels Guido J | Dir | P - Purchase | $1.06 | +30,000 | 98,750 | +44% | +$31,800 | |||||
2026-01-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $139.89 | -10,000 | 556,698 | -2% | -$1,398,911 | ||||||
| M | 2026-01-27 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $7.72 | -21,581 | 420,047 | -5% | -$166,677 | |||||
| M | 2026-01-27 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $7.71 | -13,038 | 276,610 | -5% | -$100,473 | |||||
| M | 2026-01-27 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $7.71 | -15,515 | 249,301 | -6% | -$119,631 | |||||
| DM | 2026-01-26 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale+OE | $3.00 | -17,756 | 173,999 | -9% | -$53,280 | |||||
2026-01-26 | ZIVO | Zivo Bioscience, Inc. | Cornell Alison A | Dir | P - Purchase | $8.54 | +11,709 | 279,481 | +4% | +$99,995 | ||||||
2026-01-26 | ZIVO | Zivo Bioscience, Inc. | Payne John Bernard | Pres, CEO | P - Purchase | $8.54 | +11,709 | 19,618 | +148% | +$99,995 | ||||||
2025-04-03 | CRSP | Crispr Therapeutics AG | Patel Naimish | Chief Medical Officer | P - Purchase | $32.96 | +1,508 | 1,508 | New | +$49,704 | ||||||
2026-01-14 | ZIVO | Zivo Bioscience, Inc. | Maggiore Christopher D. | Dir, 10% | P - Purchase | $8.49 | +1,766 | 519,292 | 0% | +$14,993 | ||||||
2026-01-14 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $8.49 | +1,766 | 579,638 | 0% | +$14,993 | ||||||
| M | 2026-01-23 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale | $4.72 | -116,050 | 1,317,389 | -8% | -$547,469 | |||||
2026-01-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $44.91 | -2,390 | 310,493 | -1% | -$107,330 | ||||||
| M | 2026-01-23 | TSHA | Taysha Gene Therapies, Inc. | Nolan Sean P. | CEO | S - Sale | $4.72 | -178,101 | 4,443,802 | -4% | -$840,196 | |||||
| M | 2026-01-23 | TSHA | Taysha Gene Therapies, Inc. | Alam Kamran | CFO | S - Sale | $4.72 | -102,817 | 1,443,786 | -7% | -$485,042 | |||||
| D | 2026-01-23 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale+OE | $135.00 | -115,640 | 566,698 | -17% | -$15,611,400 | |||||
| D | 2026-01-22 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $60.19 | -34,972 | 6,767 | -84% | -$2,104,965 | |||||
| D | 2026-01-22 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $45.52 | -5,000 | 12,965 | -28% | -$227,612 | |||||
2026-01-22 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $35.00 | -6,198 | 34,813 | -15% | -$216,933 | ||||||
2026-01-22 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $34.00 | -1,371 | 95,667 | -1% | -$46,614 | ||||||
2026-01-22 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $5.26 | +38,023 | 120,815 | +46% | +$200,001 | ||||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale | $1.87 | -8,934 | 173,999 | -5% | -$16,721 | |||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Siemers Eric | Chief Medical Officer | S - Sale | $1.81 | -3,226 | 255,371 | -1% | -$5,833 | |||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Zuga Matt | CFO, Chief Business Officer | S - Sale | $1.83 | -4,160 | 304,924 | -1% | -$7,607 | |||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Oconnell Daniel Joseph | CEO | S - Sale | $1.83 | -12,035 | 881,275 | -1% | -$21,993 | |||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Barton Russell | COO | S - Sale | $1.81 | -2,777 | 205,092 | -1% | -$5,031 | |||||
2026-01-22 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $12.30 | -4,000 | 128,635 | -3% | -$49,200 | ||||||
2026-01-21 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $115.60 | -908 | 46,976 | -2% | -$104,965 | ||||||
2026-01-22 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $46.71 | -14,898 | 85,660 | -15% | -$695,938 | ||||||
2026-01-21 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $26.03 | -1,977 | 197,634 | -1% | -$51,461 | ||||||
2026-01-21 | ALLO | Allogene Therapeutics, Inc. | Roberts Zachary | EVP of R, D | S - Sale | $1.56 | -26,269 | 616,866 | -4% | -$40,980 | ||||||
| D | 2026-01-22 | APGE | Apogee Therapeutics, Inc. | Fairmount Funds Management LLC | Dir | S - Sale+OE | $76.30 | -1,750,000 | 400,979 | -81% | -$133,525,000 | |||||
| D | 2026-01-20 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $4.47 | -40,000 | 913,839 | -4% | -$178,800 | |||||
| D | 2026-01-22 | DTIL | Precision Biosciences Inc | Amoroso Michael | Pres, CEO | S - Sale+OE | $4.17 | -34,799 | 196,154 | -15% | -$145,112 | |||||
| D | 2026-01-21 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $4.03 | -8,854 | 44,715 | -17% | -$35,682 | |||||
| D | 2026-01-21 | DTIL | Precision Biosciences Inc | Kelly John Alexander | CFO | S - Sale+OE | $4.03 | -15,213 | 106,448 | -13% | -$61,308 | |||||
| D | 2026-01-21 | DTIL | Precision Biosciences Inc | Smith J. Jefferson | Chief Research Officer | S - Sale+OE | $4.03 | -10,200 | 118,115 | -8% | -$41,106 | |||||
| M | 2026-01-20 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale | $57.40 | -90,000 | 219,823 | -29% | -$5,166,298 | |||||
| D | 2026-01-20 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $8.92 | -972 | 8,321 | -10% | -$8,667 | |||||
2026-01-20 | IBRX | Immunitybio, Inc. | Simon Barry J. | Dir | S - Sale | $7.20 | -151,967 | 3,091,604 | -5% | -$1,094,297 | ||||||
| DM | 2026-01-16 | IBRX | Immunitybio, Inc. | Selecky Christobel | Dir | S - Sale+OE | $5.84 | -75,000 | 0 | -100% | -$437,650 | |||||
2026-01-16 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $44.48 | -8,406 | 100,558 | -8% | -$373,880 | ||||||
2026-01-16 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $44.48 | -6,600 | 148,864 | -4% | -$293,553 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |